Disease impact on general well-being and therapeutic expectations of European Type II and Type III spinal muscular atrophy patients

Neuromuscular Disorders

Volumn 27, Issue 5, 2017, Pages 428-438

  Rouault, Françoise ^a   Christie Brown, Vanessa ^b   Broekgaarden, Ria ^c   Gusset, Nicole ^d   Henderson, Doug ^e   Marczuk, Patryk ^f   Schwersenz, Inge ^g   Bellis, Gil ^h   Cottet, Christian ^a  

^a AFM   (France)

^b SMA Trust   (United Kingdom)

^c Vereniging Spierziekten Nederland   (Netherlands)

^d SMA Schweiz   (Switzerland)

^e SMA Support UK   (United Kingdom)

^f Fundacja SMA   (Poland)

^g Deutsche Gesellschaft Für Muskelkranke E V DGM   (Germany)

^h INSTITUT NATIONAL D'ÉTUDES DÉMOGRAPHIQUES   (France)

Author keywords

Patient's perspective; Spinal muscular atrophy; Survey outcome

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; EUROPE; EXPECTATION; HUMAN; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; SPINAL MUSCULAR ATROPHY; WELLBEING; ANTICIPATION; ATTITUDE TO HEALTH; COHORT ANALYSIS; COST OF ILLNESS; DAILY LIFE ACTIVITY; HEREDITARY SPINAL MUSCULAR ATROPHY; INFANT; MIDDLE AGED; NEWBORN; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PSYCHOLOGY; YOUNG ADULT;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; AGED; ANTICIPATION, PSYCHOLOGICAL; ATTITUDE TO HEALTH; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COST OF ILLNESS; EUROPE; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; QUALITY OF LIFE; SPINAL MUSCULAR ATROPHIES OF CHILDHOOD; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85013478374     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2017.01.018     Document Type: Article

References (13)

1. [1] Sugarman, E.A., Nagan, N., Zhu, H., et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet 20 (2012), 27–32.
2. [2] Darras, B.T., Spinal muscular atrophies. Pediatr Clin North Am 62 (2015), 743–766.
3. [3] Ogino, S., Wilson, R.B., Gold, B., New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet 12 (2004), 1015–1023.
4. [4] Kaufmann, P., McDermott, M.P., Darras, B.T., et al. Muscle Study Group (MSG), Pediatric Neuromuscular Clinical Research Network for Spinal Muscular Atrophy (PNCR). Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology 79 (2012), 1889–1897.
5. [5] Barois, A., Mayer, M., Desguerre, I., et al. Spinal muscular atrophy. A 4-year prospective, multicenter, longitudinal study (168 cases). Bull Acad Natl Med 189 (2005), 1181–1198.
6. [6] Dubowitz, V., Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol 3:2 (1999), 49–51.
7. [7] Gormley, M.C., Respiratory management of spinal muscular atrophy type 2. J Neurosci Nurs 46 (2014), 33–41.
8. [8] Arnold, W.D., Kassar, D., Kissel, J.T., Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 51 (2015), 157–167.
9. [9] Wang, C.H., Lunn, M.R., Spinal muscular atrophy: advances in research and consensus on care of patients. Curr Treat Options Neurol 10 (2008), 420–428.
10. [10] Moultrie, R.R., Kish-Doto, J., Peay, H., et al. Review on spinal muscular atrophy: awareness, knowledge, and attitudes. J Genet Couns 25:5 (2016), 892–900.
11. [11] Wertz, M.H., Sahin, M., Developing therapies for spinal muscular atrophy. Ann N Y Acad Sci 1366 (2016), 5–19.
12. [12] Cano, S.J., Mayhew, A., Glanzman, A.M., et al. Rasch analysis of clinical outcome measures in spinal muscular atrophy. Muscle Nerve 49 (2014), 422–430.
13. [13] Seferian, A.M., Moraux, A., Canal, A., et al. Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial. PLoS ONE, 10, 2015, e0121799, 10.1371/journal.pone.0121799-2015.